<DOC>
	<DOCNO>NCT00190710</DOCNO>
	<brief_summary>To determine compare median survival produce combined Gemcitabine plus Paraplatin versus Gemcitabine single-agent patient NSCLC PS equal 2 .</brief_summary>
	<brief_title>A Trial Carboplatin Gemcitabine Versus Gemcitabine Alone Patients With Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologic cytologic new diagnosis NSCLC , Stage IIIB cytologically positive pleural pericardial effusion Stage IV . No prior chemotherapy , include adjuvant neoadjuvant therapy , treatment NSCLC . ECOG Performance Status 2 . Patients must least 3 week since major surgery . Patients must least 1 week since surgery , mediastinoscopy , pleuroscopy , thoracostomy . Patients must measurable disease , define lesion accurately measure least 1 dimension ( long diameter record ) great equal 20 mm conventional technique great 10 mm spiral CT scan . Any prior radiation therapy thoracic area . Active ongoing systemic infection . Prior radiation great 25 % bone marrow . ECOG PS 2 Patients know hypersensitivity gemcitabine carboplatin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>